Need professional-grade analysis? Visit stockanalysis.com
$15.32B
23.70
1,360
1.03%
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) trades on SHG in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY9.51, down 2.16% from the previous close.
Over the past year, 603707 has traded between a low of CNY9.03 and a high of CNY11.94. The stock has lost 16.4% over this period. It is currently 20.4% below its 52-week high.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd has a market capitalization of $15.32B, with a price-to-earnings ratio of 23.70 and a dividend yield of 1.03%.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections. Its injection products cover anticoagulation, anti-tumor, cardiovascular disease, as well as surgical anesthesia, anti-bacterial infection, and angiography. The company was founded in 2000 and is headquartered in Nanjing, China.
Side-by-side comparison against top Healthcare peers.